Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan
Yoshinori Watanabe,1 Yuko Asami,2 Yoko Hirano,2 Kazuhiko Kuribayashi,3 Rio Itamura,4 Takayuki Imaeda4 1Himorogi Psychiatric Institute, Tokyo, Japan; 2Medical Affairs, Pfizer Essential Health, Pfizer Japan Inc., Tokyo, Japan; 3Clinical Statistics, Pfizer Japan Inc., Tokyo, Japan; 4Clinical Research,...
Guardado en:
Autores principales: | Watanabe Y, Asami Y, Hirano Y, Kuribayashi K, Itamura R, Imaeda T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/91b2e89a07b044f78192ed42d2096ed6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Validity and test–retest reliability of the Persian version of the Montgomery–Asberg Depression Rating Scale
por: Ahmadpanah M, et al.
Publicado: (2016) -
Factors Affecting Post-Stroke Depression in Acute Ischemic Stroke Patients after 3 Months
por: Chan-Hyuk Lee, et al.
Publicado: (2021) -
Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine
por: Tokuoka H, et al.
Publicado: (2017) -
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017) -
Time course of effects of venlafaxine on migraine and generalized pruritus in a patient with depression
por: Yu Miyahara, et al.
Publicado: (2021)